Literature DB >> 30219826

Therapeutic Drug Monitoring: The Need for Practical Guidance.

Jan-Willem C Alffenaar1, Scott K Heysell2, Stellah G Mpagama3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30219826      PMCID： PMC7962896          DOI： 10.1093/cid/ciy787

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  9 in total

1.  Plasma drug activity assay for treatment optimization in tuberculosis patients.

Authors:  Scott K Heysell; Charles Mtabho; Stellah Mpagama; Solomon Mwaigwisya; Suporn Pholwat; Norah Ndusilo; Jean Gratz; Rob E Aarnoutse; Gibson S Kibiki; Eric R Houpt
Journal:  Antimicrob Agents Chemother       Date:  2011-10-03       Impact factor: 5.191

2.  Therapeutic Drug Monitoring in Tuberculosis: Practical Application for Physicians.

Authors:  Jan-Willem C Alffenaar; Simon Tiberi; Roger K Verbeeck; Scott K Heysell; Martin P Grobusch
Journal:  Clin Infect Dis       Date:  2016-10-06       Impact factor: 9.079

3.  Delayed Sputum Culture Conversion in Tuberculosis-Human Immunodeficiency Virus-Coinfected Patients With Low Isoniazid and Rifampicin Concentrations.

Authors:  Christine Sekaggya-Wiltshire; Amrei von Braun; Mohammed Lamorde; Bruno Ledergerber; Allan Buzibye; Lars Henning; Joseph Musaazi; Ursula Gutteck; Paolo Denti; Miné de Kock; Alexander Jetter; Pauline Byakika-Kibwika; Nadia Eberhard; Joshua Matovu; Moses Joloba; Daniel Muller; Yukari C Manabe; Moses R Kamya; Natascia Corti; Andrew Kambugu; Barbara Castelnuovo; Jan S Fehr
Journal:  Clin Infect Dis       Date:  2018-08-16       Impact factor: 9.079

Review 4.  Systematic Review of Salivary Versus Blood Concentrations of Antituberculosis Drugs and Their Potential for Salivary Therapeutic Drug Monitoring.

Authors:  Simone H J van den Elsen; Lisette M Oostenbrink; Scott K Heysell; Daiki Hira; Daan J Touw; Onno W Akkerman; Mathieu S Bolhuis; Jan-Willem C Alffenaar
Journal:  Ther Drug Monit       Date:  2018-02       Impact factor: 3.681

5.  Individualizing Tuberculosis (TB) Treatment: Are TB Programs in High Burden Settings Ready for Prime Time Therapeutic Drug Monitoring?

Authors:  Jotam G Pasipanodya; Tawanda Gumbo
Journal:  Clin Infect Dis       Date:  2018-08-16       Impact factor: 9.079

Review 6.  Therapeutic drug monitoring in the treatment of tuberculosis.

Authors:  Charles A Peloquin
Journal:  Drugs       Date:  2002       Impact factor: 9.546

7.  Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.

Authors:  Payam Nahid; Susan E Dorman; Narges Alipanah; Pennan M Barry; Jan L Brozek; Adithya Cattamanchi; Lelia H Chaisson; Richard E Chaisson; Charles L Daley; Malgosia Grzemska; Julie M Higashi; Christine S Ho; Philip C Hopewell; Salmaan A Keshavjee; Christian Lienhardt; Richard Menzies; Cynthia Merrifield; Masahiro Narita; Rick O'Brien; Charles A Peloquin; Ann Raftery; Jussi Saukkonen; H Simon Schaaf; Giovanni Sotgiu; Jeffrey R Starke; Giovanni Battista Migliori; Andrew Vernon
Journal:  Clin Infect Dis       Date:  2016-08-10       Impact factor: 9.079

8.  Early interventions for diabetes related tuberculosis associate with hastened sputum microbiological clearance in Virginia, USA.

Authors:  Yosra Alkabab; Suzanne Keller; Denise Dodge; Eric Houpt; Deborah Staley; Scott Heysell
Journal:  BMC Infect Dis       Date:  2017-02-06       Impact factor: 3.090

9.  Urine colorimetry to detect Low rifampin exposure during tuberculosis therapy: a proof-of-concept study.

Authors:  Isaac Zentner; Hans P Schlecht; Lorna Khensouvann; Neo Tamuhla; Michele Kutzler; Vijay Ivaturi; Jotam G Pasipanodya; Tawanda Gumbo; Charles A Peloquin; Gregory P Bisson; Christopher Vinnard
Journal:  BMC Infect Dis       Date:  2016-06-01       Impact factor: 3.090
  9 in total
  11 in total

1.  Evaluation of Saliva as a Potential Alternative Sampling Matrix for Therapeutic Drug Monitoring of Levofloxacin in Patients with Multidrug-Resistant Tuberculosis.

Authors:  Samiksha Ghimire; Bhagwan Maharjan; Erwin M Jongedijk; Jos G W Kosterink; Gokarna R Ghimire; Daan J Touw; Tjip S van der Werf; Bhabana Shrestha; Jan-Willem C Alffenaar
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

2.  Therapeutic Drug Monitoring of Anti-infective Drugs: Implementation Strategies for 3 Different Scenarios.

Authors:  Hannah Yejin Kim; Kenneth C Byashalira; Scott K Heysell; Anne-Grete Märtson; Stellah G Mpagama; Prakruti Rao; Marieke G G Sturkenboom; Jan-Willem C Alffenaar
Journal:  Ther Drug Monit       Date:  2022-02-01       Impact factor: 3.118

Review 3.  Food for thought: addressing undernutrition to end tuberculosis.

Authors:  Pranay Sinha; Knut Lönnroth; Anurag Bhargava; Scott K Heysell; Sonali Sarkar; Padmini Salgame; William Rudgard; Delia Boccia; Daniel Van Aartsen; Natasha S Hochberg
Journal:  Lancet Infect Dis       Date:  2021-03-23       Impact factor: 25.071

4.  Levofloxacin pharmacokinetics in saliva as measured by a mobile microvolume UV spectrophotometer among people treated for rifampicin-resistant TB in Tanzania.

Authors:  Sagal Mohamed; Happiness C Mvungi; Margaretha Sariko; Prakruti Rao; Peter Mbelele; Erwin M Jongedijk; Claudia A J van Winkel; Daan J Touw; Suzanne Stroup; Jan-Willem C Alffenaar; Stellah Mpagama; Scott K Heysell
Journal:  J Antimicrob Chemother       Date:  2021-05-12       Impact factor: 5.790

5.  Prospective evaluation of improving fluoroquinolone exposure using centralised therapeutic drug monitoring (TDM) in patients with tuberculosis (PERFECT): a study protocol of a prospective multicentre cohort study.

Authors:  Daan J Touw; Giovanni B Migliori; Jan-Willem Alffenaar; Simone Hj van den Elsen; Marieke Gg Sturkenboom; Onno Akkerman; Linda Barkane; Judith Bruchfeld; Geoffrey Eather; Scott K Heysell; Henadz Hurevich; Liga Kuksa; Heinke Kunst; Johanna Kuhlin; Katerina Manika; Charalampos Moschos; Stellah G Mpagama; Marcela Muñoz Torrico; Alena Skrahina; Giovanni Sotgiu; Marina Tadolini; Simon Tiberi; Francesca Volpato; Tjip S van der Werf; Malcolm R Wilson; Joaquin Zúñiga
Journal:  BMJ Open       Date:  2020-06-16       Impact factor: 2.692

6.  Integrating Pharmacokinetics and Pharmacodynamics in Operational Research to End Tuberculosis.

Authors:  Jan-Willem C Alffenaar; Tawanda Gumbo; Kelly E Dooley; Charles A Peloquin; Helen Mcilleron; Andre Zagorski; Daniela M Cirillo; Scott K Heysell; Denise Rossato Silva; Giovanni Battista Migliori
Journal:  Clin Infect Dis       Date:  2020-04-10       Impact factor: 9.079

Review 7.  Population Pharmacokinetics and Bayesian Dose Adjustment to Advance TDM of Anti-TB Drugs.

Authors:  Marieke G G Sturkenboom; Anne-Grete Märtson; Elin M Svensson; Derek J Sloan; Kelly E Dooley; Simone H J van den Elsen; Paolo Denti; Charles A Peloquin; Rob E Aarnoutse; Jan-Willem C Alffenaar
Journal:  Clin Pharmacokinet       Date:  2021-03-06       Impact factor: 6.447

8.  Practices of therapeutic drug monitoring in tuberculosis: an international survey.

Authors:  Ioana Margineanu; Onno Akkerman; Dario Cattaneo; Delia Goletti; Deborah J E Marriott; Giovanni Battista Migliori; Fuad Mirzayev; Charles A Peloquin; Ymkje Stienstra; Jan-Willem Alffenaar
Journal:  Eur Respir J       Date:  2022-04-14       Impact factor: 33.795

9.  Determination of Rifampin Concentrations by Urine Colorimetry and Mobile Phone Readout for Personalized Dosing in Tuberculosis Treatment.

Authors:  Claire Szipszky; Daniel Van Aartsen; Sarah Criddle; Prakruti Rao; Isaac Zentner; Museveni Justine; Estomih Mduma; Stellah Mpagama; Mohammad H Al-Shaer; Charles Peloquin; Tania A Thomas; Christopher Vinnard; Scott K Heysell
Journal:  J Pediatric Infect Dis Soc       Date:  2021-03-26       Impact factor: 3.164

10.  A mobile microvolume UV/visible light spectrophotometer for the measurement of levofloxacin in saliva.

Authors:  Jan-Willem C Alffenaar; Erwin M Jongedijk; Claudia A J van Winkel; Margaretha Sariko; Scott K Heysell; Stellah Mpagama; Daan J Touw
Journal:  J Antimicrob Chemother       Date:  2021-01-19       Impact factor: 5.790
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.